2024
Development and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease
Swaminathan A, McFatrich M, Mkumba L, Wright L, Redlich C, Snyder L, Reeve B, Patel D, Gulati M. Development and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease. Respiratory Research 2024, 25: 372. PMID: 39407223, PMCID: PMC11481565, DOI: 10.1186/s12931-024-03000-z.Peer-Reviewed Original ResearchConceptsCognitive interviewsContent validityExposure questionnaireMultidisciplinary teamSemi-structured interview guideEvidence of content validityFibrosing ILDsInterstitial lung diseaseRelevant exposuresFibrotic interstitial lung diseaseClinically relevant exposuresTrained interviewersInterview guideAssessment QuestionnaireQuestionnaireInterviewsLung diseaseAdultsTeamClinicPatientsSource of misunderstandingOccupational inhalation exposureValidityDisease
2023
EVALUATION OF CONTENT VALIDITY OF A NEW EXPOSURE ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH FIBROSING INTERSTITIAL LUNG DISEASES
SWAMINATHAN A, MCFATRICH M, MKUMBA L, WRIGHT L, REDLICH C, SNYDER L, REEVE B, OLSON A, GULATI M. EVALUATION OF CONTENT VALIDITY OF A NEW EXPOSURE ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH FIBROSING INTERSTITIAL LUNG DISEASES. CHEST Journal 2023, 164: a5103-a5104. DOI: 10.1016/j.chest.2023.07.3304.Peer-Reviewed Original Research
2022
Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study
Strykowski R, Patel DC, Neto MR, Hena KM, Gulati M, Maier LA, Patterson K. Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study. BMJ Open Respiratory Research 2022, 9: e001254. PMID: 35882424, PMCID: PMC9329732, DOI: 10.1136/bmjresp-2022-001254.Peer-Reviewed Original ResearchConceptsLung functionRespiratory infectionsLocal institutional review board approvalFibrotic pulmonary sarcoidosisInstitutional review board approvalNon-infected patientsInterstitial lung diseaseRespiratory viral illnessReview board approvalViral infectious diseasesImpact of infectionPulmonary sarcoidosisViral illnessClinical courseInfectious eventsStudy entryStudy cohortPoor outcomeProspective studyLung diseaseLong-term impactLife measuresSarcoidosisHigh riskGeneral populationCough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease Data From the Pulmonary Fibrosis Foundation Patient Registry
Lee J, White E, Freiheit E, Scholand M, Strek M, Podolanczuk A, Patel N, Foundation P, Bascom R, Belloli E, Bhatt N, Bhorade S, Case A, Castriotta R, Criner G, Danoff S, De Andrade J, Desai A, Glassberg M, Glazer C, Gulati M, Gupta N, Hamblin M, Huie T, Kaner R, Kass D, Kim H, Kreider M, Lancaster L, Lasky J, Limper A, Montesi S, Mooney J, Morrison L, Nambiar A, Nathan S, Natt B, Paul T, Perez R, Podolanczuk A, Raghu G, Scholand M, Shifren A, Strek M, Todd N, Walia R, Weight S, Whelan T, Wolters P. Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease Data From the Pulmonary Fibrosis Foundation Patient Registry. CHEST Journal 2022, 162: 603-613. PMID: 35337809, PMCID: PMC9808640, DOI: 10.1016/j.chest.2022.03.025.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseCough-specific QoLLeicester Cough QuestionnaireLung transplantationRespiratory hospitalizationsHigh riskPatient factorsLung diseaseDisease progressionLCQ scoreDisease severityMultivariable Cox regression modelsMultivariable proportional hazards modelsPatient-centered clinical outcomesBaseline disease severityGastroesophageal reflux diseaseHealth-related qualityRespiratory-related hospitalizationsCough-specific qualityIdiopathic pulmonary fibrosisPulmonary function parametersCox regression modelProportional hazards modelMultivariable proportional odds modelProportional odds modelOccupational Exposome and Lung Health
MacMurdo M, Culver D, Gulati M. Occupational Exposome and Lung Health. Respiratory Medicine 2022, 51-91. DOI: 10.1007/978-3-030-90185-1_4.Peer-Reviewed Original ResearchOccupational lung diseaseLung diseaseChronic occupational lung diseaseSecondary disease preventionPublic health providersRespiratory morbidityLung healthRespiratory healthWorkplace exposuresHealth providersDisease preventionDiseaseMultidisciplinary approachKey pathwaysPreventionExposomeHealthExposureMorbiditySignificant contributorMortalityCliniciansOccupational Interstitial Lung Disease
Gulati M, Maier L. Occupational Interstitial Lung Disease. 2022, 368-380. DOI: 10.1016/b978-0-12-801238-3.11503-x.Peer-Reviewed Original ResearchInterstitial lung diseaseLung diseaseRelated interstitial lung diseaseOccupational interstitial lung diseaseIdiopathic interstitial pneumoniaSecondary prevention programsRespiratory surveillance programLocal health departmentsDisease-exposure relationshipsCoal workers' pneumoconiosisInterstitial pneumoniaPathologic patternsPersonal protection equipmentDifferential diagnosisHealth departmentsPrevention programsSpecific exposuresSurveillance programConsideration of exposureHealth agenciesDiseaseRelevant exposuresExposure relationshipExposure historySimilar diseases
2020
The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods.
Wang BR, Edwards R, Freiheit EA, Ma Y, Burg C, de Andrade J, Lancaster L, Lindell K, Nathan SD, Raghu G, Gibson K, Gulati M, Mason W, Noth I, Schmidt B, Spino C, Staszak S, Stauffer J, Wolters PJ, Cosgrove GP, Flaherty KR. The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. Annals Of The American Thoracic Society 2020, 17: 1620-1628. PMID: 32776789, DOI: 10.1513/annalsats.202001-035sd.Peer-Reviewed Original ResearchConceptsInterstitial lung diseasePatient RegistryClinician accessLarge multicenter registryMean diffusing capacityPositive smoking historyPercent of patientsIdiopathic pulmonary fibrosisTime of enrollmentIndividuals 18 yearsMulticenter registrySmoking historyPulmonary fibrosisSupplemental oxygenVital capacityLung diseaseMean agePatient populationAntifibrotic therapyApplicable biomarkersClinical informationDiffusing capacityPatientsClinical sitesRegistryA Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY Learning From the Past, Looking to the Future
Lutchmansingh DD, Knauert MP, Antin-Ozerkis DE, Chupp G, Cohn L, Dela Cruz CS, Ferrante LE, Herzog EL, Koff J, Rochester CL, Ryu C, Singh I, Tickoo M, Winks V, Gulati M, Possick JD. A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY Learning From the Past, Looking to the Future. CHEST Journal 2020, 159: 949-958. PMID: 33159907, PMCID: PMC7641526, DOI: 10.1016/j.chest.2020.10.067.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute diseaseRespiratory syndromeSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Post-intensive care syndromePotential long-term complicationsCOVID-19Respiratory syndrome coronavirus 2Middle East respiratory syndromeSevere acute respiratory syndromeCoronavirus disease 2019 (COVID-19) casesPersistent respiratory symptomsLong-term complicationsCOVID-19 survivorsSyndrome coronavirus 2Acute respiratory syndromeCOVID-19 outcomesChronic complicationsPersistent symptomsRespiratory symptomsCoronavirus 2Lung diseaseNonhospitalized individualsClinical programsComplicationsAntifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
Salisbury M, Conoscenti C, Culver D, Yow E, Neely M, Bender S, Hartmann N, Palmer S, Leonard T, Baker A, Beegle S, Belperio J, Condos R, Cordova F, Culver D, Dilling D, Fitzgerald J, Flaherty K, Gibson K, Gulati M, Guntupalli K, Gupta N, Case A, Hotchkin D, Huie T, Kaner R, Kim H, Lancaster L, Lasky J, Lee D, Liesching T, Lipchik R, Lobo J, Luckhardt (formerly Joao de Andrade) T, Mageto Y, Malik N, Menon P, Morrison L, Namen A, Oldham J, Paul T, Podolanczuk A, Porteous M, Raj R, Ramaswamy M, Russell T, Sachs P, Safdar Z, Shafazand S, Siddiqi A, Sigal B, Strek M, Suliman S, Tabak J, Walia R, Whelan T. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Annals Of The American Thoracic Society 2020, 17: 1413-1423. PMID: 32574517, PMCID: PMC7640723, DOI: 10.1513/annalsats.201912-880oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisIPF-PRO RegistrySelf-rated healthAntifibrotic medicationsEnrollment windowPulmonary fibrosisDiagnosis of IPFVital capacity percentageMajority of patientsWorse self-rated healthInterstitial lung diseaseProspective outcomes registryGreater disease severityEligible patientsU.S. registriesCarbon monoxide percentageLung biopsyPatient characteristicsMedication useOutcomes RegistrySleep apneaLung diseaseDefinite diagnosisClinical trialsFamily historyEssential Components of an Interstitial Lung Disease Clinic Results From a Delphi Survey and Patient Focus Group Analysis
Graney B, He C, Marll M, Matson S, Bianchi P, Cosgrove G, Lee J, Collaborators P, Abrencillo R, Bascom R, Scholand M, Bhatt N, Case A, Chaudhary S, Culver D, Danoff S, Desai A, Dilling D, Glazer C, Gulati M, Gupta N, Hamblin M, Hamzeh N, Huie T, Kim H, King C, Kreider M, Lacamera P, Lancaster L, Luckhardt T, Mageto Y, Kottman R, McCormick J, Mehrad B, Menon P, Montesi S, Mooney J, Moore D, Moua T, Nambiar A, Oldham J, Patel D, Paul T, Perez R, Podolanczuk A, Ramaswamy M, Roe D, Saad M, Sandbo N, Schaumberg T, Schmidt S, Shea B, Shifren A, Strek M, Thavarajah K, Todd N, Veeraraghavan S, Weight S, Wolters P, Zibrak J. Essential Components of an Interstitial Lung Disease Clinic Results From a Delphi Survey and Patient Focus Group Analysis. CHEST Journal 2020, 159: 1517-1530. PMID: 33031832, PMCID: PMC7534733, DOI: 10.1016/j.chest.2020.09.256.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseILD clinicCaregiver focus groupsPhysician expertsInterstitial lung disease clinicPatient-centered medical careManagement of patientsPulmonary Fibrosis FoundationDelphi surveyILD expertsILD patientsDisease clinicMultidisciplinary careLung diseasePatient outcomesFocus groupsClinicPatientsMedical careStudy designRound 1Essential componentThree-roundCareFocus group analysisDiagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline
Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, Bargagli E, Chung JH, Collins BF, Bendstrup E, Chami HA, Chua AT, Corte TJ, Dalphin JC, Danoff SK, Diaz-Mendoza J, Duggal A, Egashira R, Ewing T, Gulati M, Inoue Y, Jenkins AR, Johannson KA, Johkoh T, Tamae-Kakazu M, Kitaichi M, Knight SL, Koschel D, Lederer DJ, Mageto Y, Maier LA, Matiz C, Morell F, Nicholson AG, Patolia S, Pereira CA, Renzoni EA, Salisbury ML, Selman M, Walsh SLF, Wuyts WA, Wilson KC. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal Of Respiratory And Critical Care Medicine 2020, 202: e36-e69. PMID: 32706311, PMCID: PMC7397797, DOI: 10.1164/rccm.202005-2032st.Peer-Reviewed Original ResearchConceptsSurgical lung biopsyHypersensitivity pneumonitisLung biopsyGuidelines CommitteeDiagnosis of HPFibrotic hypersensitivity pneumonitisNonfibrotic hypersensitivity pneumonitisTransbronchial lung biopsyTransbronchial lung cryobiopsyInterstitial lung diseaseJapanese Respiratory SocietyBronchoalveolar lavage fluidClinical practice guidelinesAmerican Thoracic SocietyPotential exposureGRADE approachLung cryobiopsyLavage fluidSerum IgGLung diseasePathological featuresThorough historyRespiratory SocietyThoracic SocietyPractice guidelines
2019
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respiratory Research 2019, 20: 227. PMID: 31640794, PMCID: PMC6805665, DOI: 10.1186/s12931-019-1190-z.Peer-Reviewed Original ResearchConceptsDisease severity measuresIPF-PRO RegistryProtein expressionLung diseaseC motif chemokine ligand 17Disease severitySeverity measuresBackgroundIdiopathic pulmonary fibrosisProgressive lung diseaseChemokine ligand 17Differential protein expressionVon Willebrand factorPulmonary fibrosisImmune activationPermeability-increasing proteinFibrosis biomarkersMultivariable modelHaemostatic responseLigand 17Control statusGlycoprotein thrombospondin-1IPFBiomarker candidatesThrombospondin-1Protein CCirculating Mitochondrial DNA Is Associated with Fibroblast Activation and Disease Progression in Scleroderma Associated Interstitial Lung Disease
Ryu C, Sun H, Winkler J, Meena S, Walia A, Minasyan M, Brandsdorfer C, Gulati M, Peng X, Herzog E. Circulating Mitochondrial DNA Is Associated with Fibroblast Activation and Disease Progression in Scleroderma Associated Interstitial Lung Disease. 2019, a7219-a7219. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7219.Peer-Reviewed Original Research
2017
Occupational lung diseases: from old and novel exposures to effective preventive strategies
Cullinan P, Muñoz X, Suojalehto H, Agius R, Jindal S, Sigsgaard T, Blomberg A, Charpin D, Annesi-Maesano I, Gulati M, Kim Y, Frank AL, Akgün M, Fishwick D, de la Hoz RE, Moitra S. Occupational lung diseases: from old and novel exposures to effective preventive strategies. The Lancet Respiratory Medicine 2017, 5: 445-455. PMID: 28089118, DOI: 10.1016/s2213-2600(16)30424-6.Peer-Reviewed Original ResearchConceptsOccupational lung diseaseLung diseaseCommon occupational lung diseaseNon-communicable lung diseasesWork-related asthmaEffective preventive strategiesMalignant lung diseaseOccupational exposurePreventive strategiesRespiratory diseaseAsthmaControl measuresDiseaseNovel exposureShort latencyGlobal causeIncidenceExposureHeavy burdenBurdenRiskManagement of workersCauseProximal causeRapid economic transitionLung Diseases, Occupational
Gulati M, Cullen M. Lung Diseases, Occupational. 2017, 485-490. DOI: 10.1016/b978-0-12-803678-5.00261-7.Peer-Reviewed Original Research
2016
Plexin C1 deficiency permits synaptotagmin 7–mediated macrophage migration and enhances mammalian lung fibrosis
Peng X, Moore M, Mathur A, Zhou Y, Sun H, Gan Y, Herazo‐Maya J, Kaminski N, Hu X, Pan H, Ryu C, Osafo‐Addo A, Homer RJ, Feghali‐Bostwick C, Fares W, Gulati M, Hu B, Lee C, Elias JA, Herzog EL. Plexin C1 deficiency permits synaptotagmin 7–mediated macrophage migration and enhances mammalian lung fibrosis. The FASEB Journal 2016, 30: 4056-4070. PMID: 27609773, PMCID: PMC5102121, DOI: 10.1096/fj.201600373r.Peer-Reviewed Original ResearchConceptsLung fibrosisPlexin C1Macrophage migrationPulmonary fibrosisBone marrow-derived cellsSynaptotagmin-7Idiopathic pulmonary fibrosisInterstitial lung diseaseMarrow-derived cellsTGF-β1 overexpressionFatal conditionLung diseaseMonocyte migrationUnrecognized observationCollagen accumulationFibrosisMice showBoyden chamberGenetic deletionLungMouse macrophagesSemaphorin receptorsMacrophagesC1s deficiencyDeficiencyNetrin‐1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin‐Induced Pulmonary Fibrosis
Sun H, Zhu Y, Pan H, Chen X, Balestrini JL, Lam TT, Kanyo JE, Eichmann A, Gulati M, Fares WH, Bai H, Feghali-Bostwick CA, Gan Y, Peng X, Moore MW, White ES, Sava P, Gonzalez AL, Cheng Y, Niklason LE, Herzog EL. Netrin‐1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin‐Induced Pulmonary Fibrosis. Arthritis & Rheumatology 2016, 68: 1251-1261. PMID: 26749424, PMCID: PMC5547894, DOI: 10.1002/art.39575.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibiotics, AntineoplasticAntibodies, NeutralizingBiomechanical PhenomenaBleomycinCase-Control StudiesCell DifferentiationCollagenCollagen Type ICollagen Type I, alpha 1 ChainFibrosisFlow CytometryFluorescent Antibody TechniqueHeterozygoteHumansLeukocyte Common AntigensLeukocytes, MononuclearLungLung Diseases, InterstitialMiceMice, KnockoutMicroscopy, Electron, ScanningNerve Growth FactorsNetrin-1ProteomicsPulmonary FibrosisReverse Transcriptase Polymerase Chain ReactionScleroderma, SystemicTissue ScaffoldsTumor Suppressor ProteinsConceptsSSc-related interstitial lung diseaseInterstitial lung diseaseFibrocyte accumulationNetrin-1Lung extracellular matrixPulmonary fibrosisLung scaffoldsBleomycin-Induced Pulmonary FibrosisPeripheral blood mononuclear cellsBlood mononuclear cellsHealthy control subjectsNovel therapeutic targetSystemic sclerosisExtracellular matrixLung fibrosisLung diseaseMononuclear cellsControl subjectsLung microenvironmentHealthy controlsScleroderma patientsAberrant anatomyLung matrixPatientsTherapeutic target
2015
Chitinase 3–like–1 and its receptors in Hermansky-Pudlak syndrome–associated lung disease
Zhou Y, He CH, Herzog EL, Peng X, Lee CM, Nguyen TH, Gulati M, Gochuico BR, Gahl WA, Slade ML, Lee CG, Elias JA. Chitinase 3–like–1 and its receptors in Hermansky-Pudlak syndrome–associated lung disease. Journal Of Clinical Investigation 2015, 125: 3178-3192. PMID: 26121745, PMCID: PMC4563747, DOI: 10.1172/jci79792.Peer-Reviewed Original ResearchMeSH KeywordsAdipokinesAdultAnimalsApoptosisBiomarkersChitinase-3-Like Protein 1Disease Models, AnimalFemaleGlycoproteinsHermanski-Pudlak SyndromeHumansInterleukin-13 Receptor alpha2 SubunitLectinsMaleMiceMice, KnockoutPulmonary FibrosisReceptors, ImmunologicReceptors, ProstaglandinRespiratory MucosaConceptsHermansky-Pudlak syndromePulmonary fibrosisChitinase 3Pulmonary fibrosis progressionFibroproliferative repairCHI3L1 levelsFibrosis progressionLung diseaseHPS-4HPS patientsIL-13Rα2Effector functionsReceptor CRTH2Epithelial apoptosisFibrosisProtective roleDisease severityPotential biomarkersCHI3L1Major causeHPS-1Abnormal localizationPatientsCell deathSeveritySmall Airways Disease Related to Occupational Exposures
Gulati M, Teng A. Small Airways Disease Related to Occupational Exposures. Clinical Pulmonary Medicine 2015, 22: 133-140. DOI: 10.1097/cpm.0000000000000094.Peer-Reviewed Original ResearchSmall airway diseaseConstrictive bronchiolitisOccupational lung diseaseAirway diseaseExposure cessationHypersensitivity pneumonitisLung diseaseMineral dust airway diseaseChronic hypersensitivity pneumonitisHigh-resolution chestCornerstone of treatmentPulmonary function testingPlain chest radiographImprovement of diseaseRange of diagnosesIdentification of exposureCorticosteroid therapyExpiratory imagingObstructive ventilatoryDisease RelatedRecalcitrant casesFunction testingDiagnostic workupPhysiologic testingTomography scanAsbestosis and environmental causes of usual interstitial pneumonia
Gulati M, Redlich CA. Asbestosis and environmental causes of usual interstitial pneumonia. Current Opinion In Pulmonary Medicine 2015, 21: 193-200. PMID: 25621562, PMCID: PMC4472384, DOI: 10.1097/mcp.0000000000000144.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisUsual interstitial pneumoniaInterstitial pneumoniaDevelopment of IPFUsual interstitial pneumonia patternRecent epidemiologic investigationsEnvironmental exposuresFibrotic lung diseaseInterstitial pneumonia patternExposure-disease relationshipsIPF patientsPneumonia patternClinical courseIPF diagnosisPulmonary fibrosisHistopathologic patternLung diseaseAsbestos exposureRadiographic changesOverall burdenAsbestosis patientsClinical challengeEpidemiologic studiesCase controlAgricultural exposures